Category Archives: Patent Eligible Subject Matter

Solicitor General’s Briefs Encourage Supreme Court to Put s. 101 Back on Track

Earlier this year, the Supreme Court issued orders to the Solicitor General to weigh in on whether or not the Court should grant cert. in two high profile Fed. Cir. decisions: Hikma Pharm. USA Inc, v. Vanda Pharm. Inc., No. … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment

October 2019 Update: Subject Matter Eligibility – A Closer Look

Guest post from Edward Sandor. Warren Woessner also posted a blog about the Updated Guidance on October 21. On October 17, 2019, the USPTO published an October 2019 Patent Eligibility Guidance Update to the earlier 2019 Revised Patent Subject Matter … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment

PTO Releases New Guidelines on Subject Matter Eligibility

On Oct. 17th, the PTO published Guidelines intended to supplement the Jan. 2019 Subject Matter Eligibility Guidelines (“2019 PEG”). The Guidelines and associated Examples are extensive. Only two of the Examples (43 and 44) are concerned with the life sciences. … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment

Athena’s “Questionable” Petition for Cert.

On October 1st, Athena filed a petition for a writ of certiorari to the Supreme Court following the Fed. Cir.’s fractured denial for its petition for rehearing en banc in Amgen v. Mayo. The original request for rehearing en banc … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , | Leave a comment